What is our Investment Case?
In becoming the trusted global leader in access to medicines, the Group has consistently delivered healthy financial performances and returns. Below are the reasons to invest in Clinigen.
By utilising Clinigen's balanced portfolio, across the services and products businesses, we offer access to medicines at the key stages of the pharmaceutical product lifecycle.
We have built a global supply chain and distribution network, organically, through acquisitions and partnerships, providing local market knowledge supported by global expertise.
We have an experienced and diverse Group and regional management, with a track record of delivering strong growth every year since inception.
We are the market-leader in CTS and Unlicensed Medicines
We are experts in the supply and distribution of unlicensed medicines.
The business can grow both through organic growth, with an increasing exposure to emerging pharmaceutical growth markets and through acquisition.
We generate strong cash returns which are underpinned by strong credit control and working capital management.
Cash generated from operations:
We have deep well-established relationships with pharmaceutical companies
Relationships with big pharma:
31 of top 50 pharma companies
> 10,000 healthcare professionals (‘HCPs’)